Phase 1 clinical trials are currently assessing different YAP/TAZ-TEAD inhibitors in patients with mesothelioma and other cancers harboring NF2/LATS1/LATS2-mutations and tumors with functional YAP/TAZ fusions or otherwise elevated YAP/TAZ levels (Fig.5). The gene discussed is LATS1; the disease is cancer.